Spots Global Cancer Trial Database for Phase II Trial for the Treatment of Relapsed Osteosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Trial for the Treatment of Relapsed Osteosarcoma
Official Title: Multicentric, Randomized Phase II Trial for the Treatment of Patients With Relapsed Osteosarcoma
Study ID: NCT02718482
Conditions
Study Description
Brief Summary: Phase II randomized study for the comparison of the Gemcitabine plus Docetaxel and the Ifosfamide treatment of patients with relapsed osteosarcoma
Detailed Description: Patients with relapsed osteosarcoma will be randomized to receive Gemcitabine plus Docetaxel or High Doses Ifosfamide (continuous infusion) every 3 weeks, up to 6 weeks
Keywords
Eligibility
Minimum Age: 4 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Fondazione del Piemonte per l'Oncologia IRCC Candiolo, Candiolo, Torino, Italy
Ospedale Gradenigo, Torino, TO, Italy
Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors, Bologna, , Italy
A.O. Universitaria Meyer, Firenze, , Italy
Istituto Giannina Gaslini, Genova, , Italy
FONDAZIONE IRCCS Istituto Nazionale dei Tumori, Milano, , Italy
Università seconda di Napoli, Napoli, , Italy
Azienda Ospedaliera di Padova, Padova, , Italy
Istituto Regina Elena - IFO, Rome, , Italy
Ospedale Infantile Regina Margherita - Unit of Paediatric Oncoematology, Torino, , Italy
Contact Details
Name: Stefano Ferrari, MD
Affiliation: Istituto Ortopedico Rizzoli
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
